Literature DB >> 24089374

Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice.

Analina R Silva1, Edenil C Aguilar, Jacqueline I Alvarez-Leite, Rafaela F da Silva, Rosa M E Arantes, Michael Bader, Natalia Alenina, Graziano Pelli, Sébastien Lenglet, Katia Galan, Fabrizio Montecucco, François Mach, Sérgio H S Santos, Robson A S Santos.   

Abstract

The classical renin-angiotensin system pathway has been recently updated with the identification of additional molecules [such as angiotensin converting enzyme 2, ANG-(1-7), and Mas receptor] that might improve some pathophysiological processes in chronic inflammatory diseases. In the present study, we focused on the potential protective role of Mas receptor activation on mouse lipid profile, liver steatosis, and atherogenesis. Mas/apolipoprotein E (ApoE)-double-knockout (DKO) mice (based on C57BL/6 strain of 20 wk of age) were fed under normal diet and compared with aged-matched Mas and ApoE-single-knockout (KO), as well as wild-type mice. Mas/ApoE double deficiency was associated with increased serum levels of atherogenic fractions of cholesterol, triglycerides, and fasting glucose compared with wild-type or single KO. Serum levels of HDL or leptin in DKO were lower than in other groups. Hepatic lipid content as well as alanine aminotransferase serum levels were increased in DKO compared with wild-type or single-KO animals. Accordingly, the hepatic protein content of mediators related to atherosclerotic inflammation, such as peroxisome proliferator-activated receptor-α and liver X receptor, was altered in an adverse way in DKO compared with ApoE-KO. On the other hand, DKO mice did not display increased atherogenesis and intraplaque inflammation compared with ApoE-KO group. In conclusion, Mas deletion in ApoE-KO mice was associated with development of severe liver steatosis and dyslipidemia without affecting concomitant atherosclerosis. Mas receptor activation might represent promising strategies for future treatments targeting both hepatic and metabolic alterations in chronic conditions clustering these disorders.

Entities:  

Keywords:  ANG-(1–7); atherosclerosis; lipodystrophy; liver steatosis; renin angiotensin system

Mesh:

Substances:

Year:  2013        PMID: 24089374     DOI: 10.1152/ajpregu.00249.2013

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  9 in total

1.  Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway.

Authors:  Johanna Schuchard; Martina Winkler; Ines Stölting; Franziska Schuster; Florian M Vogt; Jörg Barkhausen; Christoph Thorns; Robson A Santos; Michael Bader; Walter Raasch
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

Review 2.  Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.

Authors:  Sadashiva S Karnik; Khuraijam Dhanachandra Singh; Kalyan Tirupula; Hamiyet Unal
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

3.  Angiotensin 1-7 reduces mortality and rupture of intracranial aneurysms in mice.

Authors:  Ricardo A Peña Silva; David K Kung; Ian J Mitchell; Natalia Alenina; Michael Bader; Robson A S Santos; Frank M Faraci; Donald D Heistad; David M Hasan
Journal:  Hypertension       Date:  2014-05-05       Impact factor: 10.190

Review 4.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

5.  Early onset of aging phenotype in vascular repair by Mas receptor deficiency.

Authors:  Goutham Vasam; Shrinidh Joshi S; Su Yamin Miyat; Hashim Adam; Yagna P Jarajapu
Journal:  Geroscience       Date:  2021-10-18       Impact factor: 7.713

Review 6.  Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis.

Authors:  Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva
Journal:  Curr Hypertens Rep       Date:  2018-03-14       Impact factor: 5.369

Review 7.  Angiotensin-(1-7): new perspectives in atherosclerosis treatment.

Authors:  Feng Zhang; Jun Liu; Su-Fang Li; Jun-Xian Song; Jing-Yi Ren; Hong Chen
Journal:  J Geriatr Cardiol       Date:  2015-11       Impact factor: 3.327

8.  CD36/Sirtuin 1 Axis Impairment Contributes to Hepatic Steatosis in ACE2-Deficient Mice.

Authors:  Valéria Nunes-Souza; Natalia Alenina; Fatimunnisa Qadri; Josef M Penninger; Robson Augusto S Santos; Michael Bader; Luiza A Rabelo
Journal:  Oxid Med Cell Longev       Date:  2016-12-22       Impact factor: 6.543

Review 9.  The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.

Authors:  Luciana M A Borém; João F R Neto; Igor V Brandi; Deborah F Lelis; Sergio H S Santos
Journal:  Hypertens Res       Date:  2018-04-10       Impact factor: 3.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.